KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC
(MedPage Today) -- PARIS -- Targeted therapy in previously treated non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutations reduced the risk of disease progression or death by 34% compared with standard second-line chemotherapy...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Taxotere